Patients report more side effects when they know they are taking a statin than when don’t, according to findings of a recent study led by researchers at Imperial College London, funded by Pfizer, and published in The Lancet.
The European Medicines Agency has cleared use of Bial and Eisai’s sodium channel blocker Zebinix for use as a once-daily monotherapy to treat adults with newly-diagnosed partial-onset epilepsy, widening its treatment scope in the region.
The UK has the strongest and most robust clinical pipeline in Europe, with the number of drug products in development higher in the UK than anywhere else in the region, according to a new report by the BioIndustry Association.
GW Pharmaceuticals is on the brink of filing its cannabis-derived therapy Epidiolex in the US as another late-stage study highlights the drug’s efficacy in treating Dravet Syndrome, a rare and severe type of epilepsy.
The US Food and Drug Administration has cleared use of Merck & Co’s immunotherapy Keytruda to treat cancer patients identified as having a biomarker called microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).
The UK’s Competition and Markets Authority (CMA) has provisionally found that a discount scheme operated by MSD for its biologic Remicade may have restricted competition from cheaper biosimilar versions of the drug entering the market.
Set against the backdrop of a constantly changing and highly regulated environment, the PharmaTimes Marketer of the Year Awards will return to London on the 9th November 2017 to reward the best marketing talent in pharma.